Is KALV or ABEO more profitable?

Abeona Therapeutics' return on equity of -53.98% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Abeona Therapeutics N/A -53.98% -38.52%

Does the media refer more to KALV or ABEO?

In the previous week, Abeona Therapeutics had 12 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 14 mentions for Abeona Therapeutics and 2 mentions for KalVista Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.33 beat KalVista Pharmaceuticals' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABEO or INBX more profitable?

Abeona Therapeutics' return on equity of -53.98% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Inhibrx Biosciences N/A -563.90% -72.32%

Does the media prefer ABEO or INBX?

In the previous week, Abeona Therapeutics had 10 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 14 mentions for Abeona Therapeutics and 4 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.76 beat Abeona Therapeutics' score of 0.33 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABEO or XERS?

In the previous week, Abeona Therapeutics had 12 more articles in the media than Xeris Biopharma. MarketBeat recorded 14 mentions for Abeona Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.14 beat Abeona Therapeutics' score of 0.33 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COAG or ABEO more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Abeona Therapeutics N/A -53.98% -38.52%

Does the media refer more to COAG or ABEO?

In the previous week, Hemab Therapeutics had 4 more articles in the media than Abeona Therapeutics. MarketBeat recorded 18 mentions for Hemab Therapeutics and 14 mentions for Abeona Therapeutics. Hemab Therapeutics' average media sentiment score of 0.51 beat Abeona Therapeutics' score of 0.33 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MLTX or ABEO more profitable?

Abeona Therapeutics' return on equity of -53.98% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Abeona Therapeutics N/A -53.98% -38.52%

Does the media favor MLTX or ABEO?

In the previous week, MoonLake Immunotherapeutics and MoonLake Immunotherapeutics both had 14 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.53 beat Abeona Therapeutics' score of 0.33 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Abeona Therapeutics (ABEO) Competitors

$7.29 +0.23 (+3.26%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$7.03 -0.26 (-3.53%)

As of 05:50 AM Eastern

Compare

ABEO vs. KALV, INBX, XERS, COAG, and MLTX

Should you buy Abeona Therapeutics stock or one of its competitors? MarketBeat compares Abeona Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abeona Therapeutics include KalVista Pharmaceuticals (KALV), Inhibrx Biosciences (INBX), Xeris Biopharma (XERS), Hemab Therapeutics (COAG), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Abeona Therapeutics compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Abeona Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
Abeona Therapeutics	$5.82M	71.38	$71.18M	$0.97	7.52

KalVista Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Abeona Therapeutics had 12 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 14 mentions for Abeona Therapeutics and 2 mentions for KalVista Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.33 beat KalVista Pharmaceuticals' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics' return on equity of -53.98% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Abeona Therapeutics	N/A	-53.98%	-38.52%

KalVista Pharmaceuticals presently has a consensus target price of $33.25, indicating a potential upside of 23.15%. Abeona Therapeutics has a consensus target price of $19.00, indicating a potential upside of 160.63%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Abeona Therapeutics beats KalVista Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Inhibrx Biosciences?

Abeona Therapeutics (NASDAQ:ABEO) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Abeona Therapeutics' return on equity of -53.98% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Abeona Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	71.38	$71.18M	$0.97	7.52
Inhibrx Biosciences	$1.30M	1,029.45	-$140.05M	-$8.39	N/A

Abeona Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market.

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 160.63%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 64.44%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Abeona Therapeutics had 10 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 14 mentions for Abeona Therapeutics and 4 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.76 beat Abeona Therapeutics' score of 0.33 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Xeris Biopharma?

Abeona Therapeutics (NASDAQ:ABEO) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Xeris Biopharma has a net margin of 3.81% compared to Abeona Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Xeris Biopharma	3.81%	735.00%	3.24%

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abeona Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 160.63%. Xeris Biopharma has a consensus price target of $10.80, indicating a potential upside of 24.14%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Abeona Therapeutics had 12 more articles in the media than Xeris Biopharma. MarketBeat recorded 14 mentions for Abeona Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.14 beat Abeona Therapeutics' score of 0.33 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics has higher earnings, but lower revenue than Xeris Biopharma. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	71.38	$71.18M	$0.97	7.52
Xeris Biopharma	$291.85M	5.15	$550K	$0.06	145.00

Abeona Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Summary

Abeona Therapeutics beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Abeona Therapeutics (NASDAQ:ABEO) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Hemab Therapeutics had 4 more articles in the media than Abeona Therapeutics. MarketBeat recorded 18 mentions for Hemab Therapeutics and 14 mentions for Abeona Therapeutics. Hemab Therapeutics' average media sentiment score of 0.51 beat Abeona Therapeutics' score of 0.33 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.6% of Abeona Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hemab Therapeutics currently has a consensus price target of $48.00, suggesting a potential upside of 10.80%. Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 160.63%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Hemab Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has higher revenue and earnings than Hemab Therapeutics. Hemab Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Abeona Therapeutics	$5.82M	71.38	$71.18M	$0.97	7.52

Summary

Hemab Therapeutics and Abeona Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Abeona Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Abeona Therapeutics' return on equity of -53.98% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Abeona Therapeutics	$5.82M	71.38	$71.18M	$0.97	7.52

In the previous week, MoonLake Immunotherapeutics and MoonLake Immunotherapeutics both had 14 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.53 beat Abeona Therapeutics' score of 0.33 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

MoonLake Immunotherapeutics presently has a consensus target price of $24.21, suggesting a potential upside of 21.31%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 160.63%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Abeona Therapeutics beats MoonLake Immunotherapeutics on 9 of the 13 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$402.39M	$3.65B	$6.77B	$12.55B
Dividend Yield	N/A	2.22%	2.68%	9.45%
P/E Ratio	7.52	21.32	27.09	24.35
Price / Sales	71.38	176.17	485.52	74.26
Price / Cash	N/A	143.89	48.63	60.00
Price / Book	2.48	8.56	10.82	6.31
Net Income	$71.18M	$23.88M	$3.59B	$331.55M
7 Day Performance	2.39%	-3.25%	-1.80%	-0.71%
1 Month Performance	29.03%	7.59%	3.72%	0.16%
1 Year Performance	16.45%	49.87%	27.43%	19.66%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	3.4109 of 5 stars	$7.29 +3.3%	$19.00 +160.6%	+22.5%	$402.39M	$5.82M	7.52	90
KALV KalVista Pharmaceuticals	2.0497 of 5 stars	$27.00 flat	$33.25 +23.1%	N/A	$1.44B	$1.43M	N/A	100
INBX Inhibrx Biosciences	2.5459 of 5 stars	$97.14 -0.5%	$150.00 +54.4%	+297.3%	$1.43B	$1.30M	N/A	166
XERS Xeris Biopharma	3.4947 of 5 stars	$8.37 +1.1%	$10.80 +29.0%	+64.5%	$1.43B	$291.85M	139.50	290
COAG Hemab Therapeutics	2.4174 of 5 stars	$29.97 -3.3%	$41.40 +38.1%	N/A	$1.40B	N/A	N/A	72	News Coverage Analyst Forecast Analyst Revision Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. KALV, INBX, XERS, COAG, and MLTX

How does Abeona Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Abeona Therapeutics compare to Inhibrx Biosciences?

Summary

How does Abeona Therapeutics compare to Xeris Biopharma?

Summary

How does Abeona Therapeutics compare to Hemab Therapeutics?

Summary

How does Abeona Therapeutics compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. KALV, INBX, XERS, COAG, and MLTX

How does Abeona Therapeutics compare to KalVista Pharmaceuticals?

Which has preferable valuation and earnings, KALV or ABEO?

Which has more volatility and risk, KALV or ABEO?

Do institutionals and insiders believe in KALV or ABEO?

Does the media refer more to KALV or ABEO?

Is KALV or ABEO more profitable?

Do analysts prefer KALV or ABEO?

Summary

How does Abeona Therapeutics compare to Inhibrx Biosciences?

Is ABEO or INBX more profitable?

Which has higher earnings & valuation, ABEO or INBX?

Which has more risk & volatility, ABEO or INBX?

Do analysts rate ABEO or INBX?

Does the media prefer ABEO or INBX?

Do insiders & institutionals believe in ABEO or INBX?

Summary

How does Abeona Therapeutics compare to Xeris Biopharma?

Is ABEO or XERS more profitable?

Do institutionals and insiders believe in ABEO or XERS?

Do analysts recommend ABEO or XERS?

Does the media prefer ABEO or XERS?

Which has preferable valuation & earnings, ABEO or XERS?

Which has more volatility & risk, ABEO or XERS?

Summary

How does Abeona Therapeutics compare to Hemab Therapeutics?

Does the media refer more to COAG or ABEO?

Do institutionals & insiders hold more shares of COAG or ABEO?

Do analysts prefer COAG or ABEO?

Is COAG or ABEO more profitable?

Which has higher valuation and earnings, COAG or ABEO?

Summary

How does Abeona Therapeutics compare to MoonLake Immunotherapeutics?

Do institutionals and insiders hold more shares of MLTX or ABEO?

Is MLTX or ABEO more profitable?

Which has higher earnings and valuation, MLTX or ABEO?

Does the media favor MLTX or ABEO?

Which has more risk & volatility, MLTX or ABEO?

Do analysts recommend MLTX or ABEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools